



#6

# SEQUENCE LISTING

<110> Abbott Laboratories  
Collinson, Albert  
Ghayur, Tariq  
Avgerinos, George  
Dixon, Richard  
Kaymakcalan, Zehra

<120> DUAL SPECIFICITY ANTIBODIES AND METHODS OF MAKING AND USING

<130> BBC-083A US

<140> US 09/894,550

<141> 2001-06-28

<150> US 60/215,379

<151> 2000-06-29

<160> 4

<170> PatentIn version 3.1

<210> 1

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> dual specificity antigen

<400> 1

Asn Glu Ala Gln Asn Ile Thr Asp Phe

1

5

<210> 2

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> consensus sequence

<220>

<221> misc\_feature

<222> (18)..(18)

<223> Xaa is Pro or Gly

<400> 2

Met Ala Phe Leu Arg Ala Asn Gln Asn Asn Gly Lys Ile Ser Val Ala

1

5

10

15

Leu Xaa

<210> 3  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> hybrid peptide

<400> 3

Thr Lys Gly Gly Gln Asp Ile Thr Asp Phe Gln Ile Leu Glu Asn Gln  
1 5 10 15

<210> 4  
<211> 153  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> hybrid peptide

<400> 4

Ala Pro Val Arg Ser Leu Asn Cys Thr Leu Arg Asp Ser Gln Gln Lys  
1 5 10 15

Ser Leu Val Met Ser Gly Pro Tyr Glu Leu Lys Ala Leu His Leu Gln  
20 25 30

Gly Gln Asp Met Glu Gln Gln Val Val Phe Ser Met Gly Ala Tyr Lys  
35 40 45

Ser Ser Lys Asp Asp Ala Lys Ile Thr Val Ile Leu Gly Leu Lys Glu  
50 55 60

Lys Asn Leu Tyr Leu Ser Cys Val Leu Lys Asp Asp Lys Pro Thr Leu  
65 70 75 80

Gln Leu Glu Ser Val Asp Pro Lys Asn Tyr Pro Lys Lys Lys Met Glu  
85 90 95

Lys Arg Phe Val Phe Asn Lys Ile Glu Ile Asn Asn Lys Leu Glu Phe  
100 105 110

Glu Ser Ala Gln Phe Pro Asn Trp Tyr Ile Ser Thr Ser Gln Ala Glu

115

120

125

Asn Met Pro Val Phe Leu Gly Gly Thr Lys Gly Gly Gln Asp Ile Thr  
130 135 140

Asp Phe Thr Met Gln Phe Val Ser Ser  
145 150